SEC Filing Analysis: REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director was granted 8,200 stock options as a routine component of their compensation package.
• Market Impact: Neutral. This is a non-market transaction with a $0 value and is not indicative of a change in insider sentiment.

Company Information

Field	Value
Company	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Ticker Symbol	RVPH
CIK	0001742927
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Funtleyder Leslie D.
CIK	0001775394
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-18
Transaction Code	A (Grant)
Security Type	Stock Option (right to buy)
Shares Involved	8,200
Price Per Share	$0.00
Total Value	$0
Shares Owned After	8,200 (options)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted	8,200
% of Shares Outstanding	Not Available
Post-Transaction Ownership	8,200 options
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction has a value of $0 and therefore represents 0% of the company's $60 million market capitalization.
• Ownership Concentration: This is the insider's initial holding in derivative securities, representing future potential ownership upon exercise.
• Dilution Impact: As an option grant, this represents potential future dilution. The exact impact cannot be calculated without the total number of shares outstanding, but the quantity of 8,200 shares is small for a public company.
• Transaction Significance: The transaction is assessed as having low significance. It is a zero-cost equity grant, a standard form of director compensation, not an open-market trade reflecting investment sentiment.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants to directors are routine and do not typically influence short-term price action. This is a non-cash compensation event, not an investment decision by the insider.

Volume & Sentiment

• Expected Volume Impact: None. This was not an open-market transaction.
• Sentiment Indicator: Neutral. The filing reflects standard corporate governance practices regarding board compensation.

Additional Context

Transaction Notes

• Vesting Schedule: The options vest in full on the one-year anniversary of the grant date (December 18, 2026), contingent on the reporting person's continued service as a director.
• Exercise Price: The options have an exercise price of $0.5848 and expire in December 2035.